Geode Capital Management’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.2M Buy
782,199
+469,200
+150% +$4.85M ﹤0.01% 2532
2026
Q1
$2.15M Buy
312,999
+2,243
+0.7% +$12.9K ﹤0.01% 3091
2025
Q4
$1.24M Sell
310,756
-965
-0.3% -$2.32K ﹤0.01% 3313
2025
Q3
$627K Hold
311,721
﹤0.01% 3533
2025
Q2
$387K Sell
311,721
-362,090
-54% -$451K ﹤0.01% 3636
2025
Q1
$822K Buy
673,811
+12,980
+2% +$21.1K ﹤0.01% 3371
2024
Q4
$1.19M Buy
660,831
+9,534
+1% +$34.5K ﹤0.01% 3304
2024
Q3
$3.32M Buy
651,297
+479,700
+280% +$3.39M ﹤0.01% 2952
2024
Q2
$1.22M Buy
171,597
+104,971
+158% +$699K ﹤0.01% 3236
2024
Q1
$183K Hold
66,626
﹤0.01% 3972
2023
Q4
$179K Hold
66,626
﹤0.01% 3983
2023
Q3
$176K Buy
66,626
+2,612
+4% +$7.12K ﹤0.01% 4036
2023
Q2
$179K Hold
64,014
﹤0.01% 4091
2023
Q1
$186K Hold
64,014
﹤0.01% 4088
2022
Q4
$229K Sell
64,014
-125
-0.2% -$371 ﹤0.01% 4026
2022
Q3
$207K Hold
64,139
﹤0.01% 4191
2022
Q2
$193K Sell
64,139
-48,882
-43% -$231K ﹤0.01% 4291
2022
Q1
$948K Sell
113,021
-2,651
-2% -$24.7K ﹤0.01% 3643
2021
Q4
$1.21M Buy
115,672
+38,768
+50% +$578K ﹤0.01% 3622
2021
Q3
$1.38M Buy
+76,904
New +$1.59M ﹤0.01% 3524

Other funds holding CLYM

Geode Capital Management's CLYM Position: Q2 2026 in Review

Geode Capital Management increased its Climb Bio (CLYM) stake by 150% in Q2 2026, buying an estimated $4.85M and bringing the position to 782,199 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Geode Capital Management first reported a position in CLYM in Q3 2021 and has held it in 20 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Geode Capital Management held 782,199 shares of Climb Bio worth $10.2M as of Q2 2026.
  • Geode Capital Management bought 469,200 Climb Bio shares in Q2 2026, an estimated $4.85M.
  • Climb Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2532 holding.
  • Geode Capital Management first reported a position in Climb Bio in Q3 2021 and has held it in 20 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.